Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer

Mary Cianfrocca, William J. Gradishar*

*Corresponding author for this work

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

The question of combination versus single-agent chemotherapy in the setting of metastatic breast cancer (MBC) is an often-debated issue. Many single agents have activity in this setting and the potential for significant synergism between chemotherapy agents has led to many combination chemotherapy trials. This article defends the position that combination chemotherapy is the optimal approach for patients with MBC.

Original languageEnglish (US)
Pages (from-to)673-675
Number of pages3
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume5
Issue number8
DOIs
StatePublished - Sep 2007

Keywords

  • Chemotherapy
  • Combination therapy
  • Metastatic breast cancer
  • Polychemotherapy
  • Single agent

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Counterpoint: The argument for combination chemotherapy in the treatment of metastatic breast cancer'. Together they form a unique fingerprint.

  • Cite this